Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Marzewski, D. J.
Right arrow Articles by Brown, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Marzewski, D. J.
Right arrow Articles by Brown, P.
NEUROLOGY 1988;38:1131
© 1988 American Academy of Neurology

Creutzfeldt-Jakob disease following pituitary-derived human growth hormone therapy

A new American case

D. J. Marzewski, MD, J. Towfighi, MD, M. G. Harrington, MB, ChB, MRCP, C. R. Merril, MD and P. Brown, MD

From the Department of Neurology (Dr. Marzewski), Geisinger Medical Center, Danville, PA; the Division of Neuropathology (Dr. Towfighi), Department of Pathology, Milton S. Herahey Medical Center, Hershey, PA; and the Biochemical Genetics Section, Clinical Neurogenetics Branch (Drs. Harrington and Merril), and the Laboratory of CNS Studies (Dr. Brown), National Institute of Neurological and Communicative Disorders and Stroke, National Institutes of Health, Betheada, MD.

A fourth histologically-confirmed American case of Creutzfeldt-Jakob disease (CJD) related to human growth hormone (hGH) therapy is reported. Like kuru, the illness was dominated by cerebellar signs and relatively little mental deterioration. The diagnosis was strongly supported premortem by the presence of two abnormal 30 kDa proteins in the CSF that are seen almost exclusively in CJD. The characteristic clinical picture coupled with such biochemical data allow a reasonably accurate premortem diagnosis of hGH-related iatrogenic CJD to be made.

Address correspondence to Dr. Brown, Building 36, Room 5B21, NINCDS, NIH, Bethesda, MD 20892. Address reprint requests to Dr. Marzewski, Department of Neurology, Geisinger Medical Center, Danville, PA 17822.

Received September 2, 1987. Accepted for publication in final form November 25, 1987.




This article has been cited by other articles:


Home page
 NeurologyHome page
P. Brown, J.-P. Brandel, M. Preese, and T. Sato
Iatrogenic Creutzfeldt-Jakob disease: The waning of an era
Neurology, August 8, 2006; 67(3): 389 - 393.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
R J Cordery, M Hall, L Cipolotti, S Al-Sarraj, D G O'Donovan, L Davidson, P Adlard, and M N Rossor
Early cognitive decline in Creutzfeldt-Jakob disease associated with human growth hormone treatment
J. Neurol. Neurosurg. Psychiatry, October 1, 2003; 74(10): 1412 - 1416.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
G. Hsich, K. Kenney, C. J. Gibbs, K. H. Lee, and M. G. Harrington
The 14-3-3 Brain Protein in Cerebrospinal Fluid as a Marker for Transmissible Spongiform Encephalopathies
N. Engl. J. Med., September 26, 1996; 335(13): 924 - 930.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
S. B. Prusiner
Genetic and Infectious Prion Diseases
Arch Neurol, November 1, 1993; 50(11): 1129 - 1153.
[Abstract] [PDF]

Home page
 JAMAHome page
J. E. Fradkin, L. B. Schonberger, J. L. Mills, W. J. Gunn, J. M. Piper, D. K. Wysowski, R. Thomson, S. Durako, and P. Brown
Creutzfeldt-Jakob Disease in Pituitary Growth Hormone Recipients in the United States
JAMA, February 20, 1991; 265(7): 880 - 884.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1988 by AAN Enterprises, Inc.